Dollars for Docs lists the following 10 drugs for which companies paid the most in payments to physicians last year:
1. Xarelto (a blood thinner) — $28.4 million
2. Humira (rheumatoid arthritis drug) — $24.9 million
3. Invokana (drug for diabetes) — $20.9 million
4. Viekira (hepatitis C drug) — $19.2 million
5. Eliquis (blood thinner) — $18.8 million
6. Bydureon (diabetes drug) — $18.5 million
7. Androgel (testosterone drug)— $15.3 million
8. Synthroid (thyroid drug)—$14.7 million
9. Lupron (synthetic hormone) — $14.3 million
10. Victoza (diabetes drug)— $11.9 million
More articles on quality & infection control:
The Joint Commission addresses confusion surrounding provider text messaging: 5 things to know
Global disposable syringes market to surge to $9.9B by 2024: 4 points
Study: ’32k fewer patients would die every year if male physicians could achieve the same outcomes as female physicians’
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.